Citadel Advisors
ORMP icon

Citadel Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Citadel Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,800
Closed -$51.3K – 13732
2025
Q2 		$51.3K Buy
22,800
+11,600
+104% +$25.6K ﹤0.01% 11754
2025
Q1 		$24K Sell
11,200
-6,200
-36% -$14.3K ﹤0.01% 13015
2024
Q4 		$42.1K Buy
17,400
+13,400
+335% +$31.8K ﹤0.01% 12562
2024
Q3 		$9.76K Buy
+4,000
New +$9.75K ﹤0.01% 13239
2024
Q2 		– Sell
-8,300
Closed -$24.2K – 15071
2024
Q1 		$24.2K Sell
8,300
-1,300
-14% -$3.63K ﹤0.01% 12869
2023
Q4 		$22.2K Sell
9,600
-4,800
-33% -$10.3K ﹤0.01% 12533
2023
Q3 		$37.6K Sell
14,400
-19,100
-57% -$60.1K ﹤0.01% 12069
2023
Q2 		$120K Buy
33,500
+1,800
+6% +$5.77K ﹤0.01% 10658
2023
Q1 		$69.1K Sell
31,700
-38,700
-55% -$123K ﹤0.01% 11751
2022
Q4 		$847K Sell
70,400
-16,300
-19% -$127K ﹤0.01% 7136
2022
Q3 		$562K Sell
86,700
-300
-0.3% -$2.43K ﹤0.01% 8204
2022
Q2 		$398K Sell
87,000
-5,000
-5% -$26.7K ﹤0.01% 9147
2022
Q1 		$796K Sell
92,000
-12,500
-12% -$128K ﹤0.01% 8231
2021
Q4 		$1.49M Buy
104,500
+27,800
+36% +$581K ﹤0.01% 6896
2021
Q3 		$1.69M Sell
76,700
-26,400
-26% -$450K ﹤0.01% 6801
2021
Q2 		$1.38M Sell
103,100
-21,800
-17% -$249K ﹤0.01% 7509
2021
Q1 		$1.27M Buy
124,900
+83,900
+205% +$689K ﹤0.01% 7509
2020
Q4 		$174K Buy
+41,000
New +$133K ﹤0.01% 9838
2020
Q3 		– Sell
-49,900
Closed -$176K – 10554
2020
Q2 		$176K Sell
49,900
-20,300
-29% -$68.1K ﹤0.01% 8620
2020
Q1 		$213K Buy
70,200
+8,000
+13% +$35.1K ﹤0.01% 7908
2019
Q4 		$320K Buy
+62,200
New +$233K ﹤0.01% 7491
2015
Q4 		– Sell
-9,100
Closed -$50K – 9053
2015
Q3 		$50K Sell
9,100
-2,100
-19% -$13.2K ﹤0.01% 7582
2015
Q2 		$64K Buy
+11,200
New +$76.7K ﹤0.01% 7489
2015
Q1 		– Sell
-2,600
Closed -$12K – 8754
2014
Q4 		$12K Sell
2,600
-5,800
-69% -$38.1K ﹤0.01% 8077
2014
Q3 		$68K Buy
+8,400
New +$74.7K ﹤0.01% 6692

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's ORMP Position: Q1 2026 in Review

Citadel Advisors reduced its Oramed Pharmaceuticals (ORMP) stake by 50% in Q1 2026, selling an estimated $330K and leaving 98,629 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #10221.

Citadel Advisors first reported a position in ORMP in Q4 2014 and has held it in 21 quarters since. The position peaked at $7.63M in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Citadel Advisors held 98,629 shares of Oramed Pharmaceuticals worth $335K as of Q1 2026.
  • Citadel Advisors sold 97,391 Oramed Pharmaceuticals shares in Q1 2026, an estimated $330K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10221 holding.
  • Citadel Advisors first reported a position in Oramed Pharmaceuticals in Q4 2014 and has held it in 21 quarters since.
  • Citadel Advisors's Oramed Pharmaceuticals position peaked at $7.63M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.